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Peptidoglycan occurs naturally in cell wall structures of almost all types of bacteria. 
Muramyl dipeptide (MDP) is a fragment of peptidoglycan, which consists of N-
acetylmuramic acid that is attached to a dipeptide of L-alanine and D-iso-glutamine. 
Peptidoglycan is a potent immunostimulant and MDP has been identified as the minimal 
structure required of peptidoglycan for activating the innate immune system.  MDP 
engages the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) 
receptor and activates the receptor. Importantly, MDP shows a promising vaccine 
adjuvant property. However, high toxicity, hydrophilicity, rapid elimination from the 
biological system, and other drawbacks associated with MDP prevent it from being used 
in clinics. In this study, novel MDP analogues have been designed and synthesized in 
order to improve the molecule’s biological activity. The modification in these analogues 
was applied within the dipeptide component, that is, using an artificial aromatic amino 
acid residue in place of the D-iso-glutamine residue in natural MDP. N-acetylation of 4-
amino-3-nitrobenzoic acid was the starting point of the synthesis pathway. Next, the 
nitro group was reduced and coupled with L-alanine to form the main building block 14. 
The incorporation of different lengths of lipid chains at the C-terminal of the dipeptide 
mimic 14 resulted in lipophilic dipeptide analogues 11, 12 and 13. The dipeptide mimics 
11 - 14 were then coupled with an N-acetylmuramic acid derivative 36 to provide 
protected MDP analogues 37 - 40. The first set of MDP analogues 4 - 6 were obtained 
by applying 37, 38, and 39 under the global deprotection reaction using Pd/C as the 
catalyst in a hydrogen atmosphere to remove both benzyl and benzylidene groups. The 
second set of analogues 7 - 9 were formed by treating 37 - 39 with trifluoroacetic acid to 
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remove only the benzylidene group. Attempts at forming hydrophilic mimics 2 and 3 
were not entirely successful due to a technical obstacle during the last step of the 
deprotection reactions. Ultimately, biological evaluation will determine the potential of 
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1.1 Biological background  
1.1.1 The immune system 
The immune system, which comprises special cells, tissues, proteins, and organs, 
protects the body against disease-causing microorganisms. The system has two 
separate arms that collaborate with each other to protect the host. The immune system 
can either be innate or adaptive. An innate immune system is a non-specific defense 
mechanism which comes into play as a first line of defense in the body. Unlike innate 
immunity, adaptive immunity is specific to the antigen and, thus, it is more complex1. 
Moreover, the immune system follows a sequence of steps known as the immune 
response towards invading microorganisms and foreign substances that attack the body 
and cause disorders. The system begins its response by processing and recognizing an 
antigen. It then proceeds to generate an army of immune cells specifically designed to 
invade the antigen. An adaptive system is also responsible for generating a future 
response that is more efficacious with respect to the same antigen2.   
 
1.1.2 The innate immune system  
The innate immune system acts as the first line of defense against invading pathogens. 
The mechanisms involved in this system include physical blocks such as the skin, 
chemicals within the blood, and immune cells that invade and destroy any foreign 
microorganisms in the body. The cells in an innate immune system include neutrophils, 
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macrophages, eosinophils, basophils, natural killer cells, and dendritic cells3,4. The 
innate immunity is responsible for detecting and responding to microbial invasion. It 
does that by using specific pattern recognition receptors (PRRs) which are activated by 
pathogen associated molecular patterns (PAMPs). 
 
1.1.3 Recognition receptors of innate immunity 
The chemical characteristics of a particular antigen are responsible for activating the 
response of an innate immune system. Specifically, the innate immune system uses a 
group of (PRRs) to identify pathogenic products by recognizing unique (PAMPs). 
PAMPs are preserved structures that are characterized by pathogenic structures. 
Bacterial products are examples of the common PAMPs such as peptidoglycan, 
lipoteichoic acid, lipopolysaccharide (LPS), as well as viral RNA2,5. Many PRRs of the 
innate immune system have been identified. Toll-like receptors (TLRs) are the oldest 
PRRs that have been identified and studied for decades6. Recently, PRRs have been 
classified into five families based on distinct genetic and functional differences, 
including: TLRs; nucleotide-binding and oligomerization domain (NOD)-like receptors 
(NLRs); retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs); C-type lectins 
(CTLs); and absent-in-melanoma (AIM)-like receptors (ALRs)7,8. TLRs and CTLs are 





1.1.4 NOD-like receptors as innate immune system receptors  
 NLRs are a special group of intracellular receptors which play a critical role in the 
innate immune system through the detection of intracellular PAMPs and ‘danger-
associated molecular patterns’ (DAMPs)9. Recently, NLRs, namely a family of proteins, 
have been identified as a target for muramyl dipeptide (MDP) derivatives. NLRs are 
readily available in nonimmune cells, dendritic cells, macrophages, and lymphocytes. 
They contain a unique form of PRRs, which play a crucial role in the detection of 
dangerous components such as cytosolic microbial products. Receptors of this family 
share a general tripartite domains structure that consists of the following: a carboxy (C)-
terminal leucine rich repeat (LRR) domain, a central NOD domain (also known as 
NACHT domain) that has ATPase activity; and an amino (N)-terminal domain which 
controls the protein-protein interaction cassettes such as CARD (caspase activity and 
recruitment domain) or pyrin (PYD). PYD is a protein domain, specifically a branch of 
protein motif known as the death fold; it allows a pyrin domain-containing protein to 
interact with other proteins that contain a pyrin domain. NOD1 and NOD2 are the most 
common NLRs10. NOD1 is composed of C-terminal LRR, a central NOD and N-terminal 
domain that consists of a single CARD, while NOD2 has a C-terminal LRR, a central 
NOD and a N-terminal domain that contains two CARDs11,12 (Figure 1). The two CARD 
domains referd to the caspase activity and recruitment domain; the NOD domain11 is the 
site for nucleotide-binding oligomerization; and the LRR domain is usually where ligand 












Figure 1: Structural domains in NOD2 
 
 
1.1.5 NOD2 signaling pathway 
The detection of the peptidoglycan fragment MDP activates the cytosolic recognition 
pattern receptor (NOD2) to produce an inflammatory immune response. The other 
effects of the activation include the release of cytokines, the generation of antimicrobial 
peptides such as defensins, the induction of autophagy, and the upregulation of 
interleukin 1β13. 
 
MDP is a critical player in the NOD2 signaling pathway since it acts as a ligand for 
NOD2. MDP enters a cell and binds itself to NOD2. After the activation of NOD2, it is 
ready to initiate the CARD-CARD interactions between NOD2 and receptor-interacting 
serine–threonine kinase RICK. Moreover, RICK polyubiquitination links to IKappaB 
kinase (IKK) complexes, a critical step in permitting polyubiquitylation of the NF-kB (IkB) 
kinase g (IKKg) inhibitors.  
 
NOD CARD CARD LRR -COO- 






Figure 2: NOD2 signaling pathway. 1. MDP is introduced into this system. 2. Binds to NOD2 receptor 
via LRR. 3. NOD domain interacts with RICK mediator. 4. RICK joins the activated NOD2 receptor to 
activate IKK complex. 5. Simultaneous binding of the IKK complex to NOD2 through RICK/RIP2 results in 
ubiquitination of IKKɣ (NEMO). 6. NEMO degradation allows the IKKα and IKKβ subunits to phosphorylate 
IkBα. 7. This phosphorylation event leads to the dissociation of IB from NF-β. 8a. IB is degraded by the 
proteasome. 8.b the active form of NF-kβ is free. 9. NF-β translocases into the nucleus. 10. NF-kβ 
stimulate the production of pro-inflammatory cytokines. 
 
The polyubiquitylation of the inhibitors causes a phosphorylation event of IKKβ, which in 
turn leads to the phosphorylation of IkB. The phosphorylation processes cause IkB to 
dissociate from NF-kB. NF-kB then translocates towards the nucleus. The translocation 
enhances the transcription of several anti-inflammatory and pro-inflammatory cytokines 
alongside defensins12. Some important cytokines include IL-10, IL-8, IL-1β, and TNF-α. 




1.2 Muramyl dipeptide  
1.2.1 MDP as a trigger of the innate immune system  
MDP is the smallest bioactive peptidoglycan motif (Figure 3) that occurs in all bacteria. 
MDP was discovered in 1974. Scientists believed that it was the minimal structure 
required for biological effects, including activity in Freund’s complete adjuvant (FCA), 
one of the most potent and widely used adjuvants in experimental animal models to 
date14. MDP can be used for improving the adjuvant activities in vaccines. MDP consists 
of N-acetylmuramic acid connected to the N-terminal of an L-alanine D-isoglutamine 
dipeptide (Figure 3). The immune system recognizes MDP as a microorganism-
associated molecular component that stimulates the NALP3 (NACHT, LRR and PYD 
domains-containing protein 3) inflammasome, which activates the production of 









Bacterial cell wall MDP and glucosaminyl-MDP (GMDP, Figure 4) are responsible for 
the activation of innate immunity. YB1 (Y box binding protein) and NOD2 are the two 
principal receptor targets in an innate immune system15. NOD2 targets are responsible 
for recognizing lignds such as MDP and all its derivatives. NOD2 plays a critical role in 
both innate and adaptive immunities by regulating chemokines, cytokines, and 
producing antimicrobial peptides14.  
 
 
Figure 4: Glucosaminyl-MDP (GMDP)16 
 
1.2.2 Structure-activity relationship of MDP 
Girardin et al.17 described MDP and its analogues as NOD2/CARD15 ligands. The 
recognition process of NOD2/CARD15 and its ligands is specific to the L-D isomer of 
the alanine-iso-glutamine dipeptide moiety, while analogues with L-L or D-D 
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configuration are not recognized. Researchers have linked MDP’s potent adjuvant 
activity to CIAS1/NALP3/cryopyrin inflammasome activation15.  
 
However, until 2012, there was not enough detailed information about MDP-NOD2 
interactions. Since then, some researchers reported that the first amino acid of MDP (L-
alanine) is the most important component in the immunomodulatory activity of this 
compound17. Other scientists have indicated that the interaction between NOD2 and 
MDP required an intact MurNAc sugar group substituted in a peptide chain of MDP18. In 
fact, many studies have been done to further understanding the interaction between 
MDP and NOD219. For instance, Mo et al. reported in 2012 that NOD2 is activated by 
MDP and ATP20. First, NOD2 binds and hydrolyzes ATP. Next, it binds itself directly to 
MDP and interacts with known NOD2-interacting proteins. As a result of this interaction, 
macrophages and other immune cells produce cytokines such as TNF-, IL-1, IL-6, IL-
8, along with secretion of nitric oxide (NO)21. These molecules are quite important not 
only in alerting the immune cells, but also in encouraging them to fight the rapidly 
multiplying bacteria. 
 
1.2.3 Previous MDP analogues and their biological properties 
There are many concepts that scientists focused on while designing and synthesizing 
MDP analogues. Solubility, lipophilicity, permeability and biological activity are the 
properties that are given most attention to when MDP analogues are examined. 
Reaching the balance between water solubility and lipophilicity helps to resolve issues 
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of rapid elimination and poor membrane penetration, which are the most significant 
drawbacks of a naturally occurring MDP structure.   
 
Numerous studies have designed and synthesized lipophilic MDP derivatives through 
conjugating with carriers or modifying MDP structure. Lipophilic derivatives and 
lipophilic delivery carrier systems have shown an increase in the adjuvant activity 
compared to MDP22. This result indicates that having lipophilic characteristics in MDP 
analogues improves their pharmacological properties. Important examples of lipophilic 
MDP derivatives include romurtide and muramyl tripeptide phosphatidylethanolamine 
(MTP-PE, also known as Mafimuratide, Figure 5). Mafimuratide has similar 
immunostimulatory effects as the natural MDP23. Furthermore, Mafimuratide has 
entered clinical trials as a component of an influenza vaccine24. It has also been 
approved for the treatment of early stage osteosarcoma in combination with 






Figure 5. Mafimuratide (MTP-PE)29 
 
Another well-known MDP analogue is called MDP-C (Figure 6). This analogue is free 
from pyrogenicity, allergenicity and toxicity. In addition, MDP-C presents a significant 
potential for immunotherapeutic prophylactic application in infectious diseases caused 




Figure 6. MDP-C structure  
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Perhaps one of the most notable modifications in all synthesized MDP analogues is the 
replacement of the MurNAc block. MDP derivatives which lack carbohydrate moiety are 
called desmuramyl peptides (DMPs)11,26, for example, FK-565 (Figure 7) DMPs are less 
hydrophilic than the parent MDP molecule. Even though DMPs do not have 
carbohydrate residues, they are still recognized by the immune system receptors. 
Therefore, they are able to activate the innate immune system against microbial 
infections. They are also known to exhibit significant adjuvant activity and remarkable 
antitumor potency. Studies on DMPs prove that the sugar N-acetylmuramyl moiety 
(MurNAc) is not required for NOD2 activation11,22.  
 
 
Figure 7. Structure of FK-565, an example of DMPs14 
 
Murabutide (MB), temurtide, nor-MDP and glucosaminyl-MDP (GMDP) are the 
hydrophilic analogues which have recently been selected for clinical development by 
researchers11. Nor-MDP does not have a methyl group in the same position as in MDP. 
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This modification helps to reduce the chirality effects in the lactic acid moiety. As a 
result, nor-MDP exhibits comparable stimulating activity and less toxicity. MB is also 
known as N-acetylmuramyl-L-alanyl-D-glutamine-n-butyl ester (Figure 8). Very simple 
modification is applied on MDP structure to form MB by having a butyl ester group in the 
dipeptide moiety, which is an apyroginic derivative of MDP27. MB enhances non-specific 
resistance to bacterial and viral infections28. A recent study found that MB is capable of 
boosting the antiviral and anti-inflammatory effects of IFN-α and it potentiates the 
antitumor activity of both IFN-α and IL-2 in vitro when it is combined with these 
cytokines27. In addition, MB is capable of inhibiting HIV-1 replication in acutely infected 
monocyte-derived macrophages (MDM) and dendritic cells11.  
 
 




1.2.4 The lipophilicity of MDP  
Since the discovery of MDP, many MDP analogues have been designed and 
synthesized. One crucial property that affects the pharmacological properties of MDP is 
its lipophilicity29. Lipophilic modification of MDP helps eliminate the drawbacks of MDP 
such as the poor penetration through cell membrane and the rapid elimination from the 
biological system24. Many lipophilic analogues have been described in several previous 
research studies14,15,21,30. Biological studies showed that lipophilic MDP analogues 
present more favorable uptake profile than the relatively more polar MDP.  Having 
lipophilic property would allow such MDP analogues to be incorporated into liposome, a 
favorable drug delivery system for both polar and non-polar small molecule drugs.   
 
Muramyl tripeptide phosphatidylethanolamine (MTP-PE, Figure 5) is a synthetic 
lipophilic analogue of MDP. The lipophilic chains of the molecule give it a 
longer elimination half-life than the natural MDP molecule. MTP-PE (also known as 
Mifamurtide) has been developed for clinical use for the treatment of osteosarcoma, a 
kind of bone cancer mainly affecting children and young adults. The drug was approved 
in Europe in March 200929.  
 
B30-MDP is another example of lipophilic MDP analogues. The molecule bears a 
lipophilic acyl chain with 30 carbon atoms at the 6-O-posiiton of the glucosaminyl sugar 
residue (Figure 9). The B30-MDP was evaluated for its adjuvant activity and found 





Figure 9. Structure of B30-MDP32. 
 
Lipophilic MDP analogues enter the cell through passive diffusion across the cell 
membrane, which depends on the lipophilic character of these molecules14,33,34. 
Structure-activity relationship (SAR) studies of MDP analogues have shown that the 
introduction of lipophilic substituents into MDP may increase its adjuvant activity in the 
potentiation of immune responses to antigens and vaccines35.  It is believed that 
hydrolyzing the lipophilic MDP analogues inside the cells is an essential step to produce 
a hydrophilic metabolite which activates NOD214. These earlier findings clearly indicate 
that lipophilic modification is a viable strategy in creating novel lipophilic MDP 





1.3. The therapeutic potential of NOD2 signaling pathway 
NOD-like receptors (NLRs) including NOD1 and NOD2 play critical roles in pathogen 
recognition and immune responses. For example, bacterial components such as 
peptidoglycan are sensed by NOD1 and NOD2 receptors. Therefore, NOD1 and NOD2 
have been known to be responsible for the detection of bacteria and the production of 
pro-inflammatory cytokines by activating signaling pathways such as NF-kβ and Caspase 
1. These pro-inflammatory cytokines promote the development of effective defense 
mechanisms which ultimately lead to the clearance of bacteria in the host36.  
 
NLRs also play important roles in mediating the immunostimulatory activity of adjuvant 
molecules, as NOD2 is able to bind to MDP. MDP or any other molecular adjuvants can 
enhance the adaptive immune responses toward antigens by influencing the innate 
immunity37.  
 
Modulating the innate immune response by blocking the binding site of NLRs or any 
central molecules in the signaling pathway is a developed therapeutic procedure for 
human autoimmune and chronic inflammatory diseases. One of the successful 
undertakings of modulation is using kinase inhibitors to block RIPK2, a serine/threonine 
protein kinase which is a component of signaling complexes in both the innate and 
adaptive immune pathways. Moreover, compounds capable of blocking NOD2 signaling, 
such as diterpene-based molecules, have been used as anti-inflammatory compounds38. 
For example, such molecules can be used to treat inflammatory diseases such as Crohn’s 
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disease, asthma, and arthritis37. On the other hand, molecules capable of enhancing 
NOD2 signaling pathway can be useful to fight against bacterial/viral infections. 
 
1.4 Vaccine adjuvant 
Adjuvants are vaccine ingredients that facilitate the generation of a stronger response 
within the immune system in the body. As such, adjuvants enable vaccines to work better. 
Certain vaccines made from dead germs contain natural adjuvants39. Nonetheless, most 
contemporary vaccines contain only a small portion of germs, i.e., their proteins, instead 
of the entire bacteria or virus. Therefore, it’s critical to include an adjuvant in a vaccine to 
not only stimulate the adaptive responses of the immune system, but also to activate the 
innate immune response to prevent unwanted side effects of the vaccine. Adjuvants have 
been used in both therapeutic and protective vaccines.  
 
It is well recognized that PRRs of innate immunity such as TLRs and NLRs can modulate 
and control the generation of humoral and cellular immune responses. Therefore, PRR 
agonists can be strong vaccine adjuvants due to their ability to activate the innate immune 
responses mediated by these receptors. MDP has been well studied for its adjuvant 
property which enhances and directs the body’s adaptive immune response towards 
vaccine antigens by triggering and activation of the NOD2 receptor40. 
 
Monocytes, macrophages and dendritic cells (DCs) are the antigen presenting cells 
(APCs) and responsible for innate-adaptive cross-function. Activation of NLRs initiates 
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the cellular defense mechanism which results in cytokine production as well as activation 
of APCs to modulate the adaptive responses. The stimulation of NLRs upregulates MHC 
class II on DCs. Specifically, NOD2 upregulates MHC class II CD4+ T-cell response39. 
Two principal forms of lymphocytes (T and B cells) mediate this type of response41.  
Based on the TH profiles such as TH1, TH17, and TH2, humoral and/or cellular responses 
can be produced. With respect to humoral response, the generation of IgG2 and IgG1 
antibodies is the primary target of the adaptive response in vaccination41.  
  
Researchers have recommended that the use of MDP as an adjuvant should remain 
restricted to the manufacture of veterinary vaccines, but not human vaccines. The reason 
is that MDP has proved to be extremely pyrogenic and unfit for human consumption41. 
The pyrogenic nature of MDP has inspired scientists to come up with less pyrogenic MDP 
derivatives that have high immunomodulatory potential and adjuvanticity. MDP(D-Glu2)-
OCH3 and N-glycocyl-MDP (Figure 10) are some of the MDP derivatives with higher 














Figure 10. Structure of MDP(D-Glu2)-OCH3 and N-glycocyl-MDP42,43 
 
1.5 Anticancer treatments by MDP analogues 
Several anticancer treatment methods exist, and they are selected by physicians 
depending on the type of cancer and its stage. They include surgery, radiation therapy, 
chemotherapy, immunotherapy, targeted therapy, hormone therapy, and stem cell 
transplantation. Immunotherapy is a form of cancer treatment that boosts the immune 
system’s ability to fight cancer.  
 
The use of MDP to initiate NOD2 signaling is one of the many immunotherapies used to 
treat cancer44. In the last decade, researchers have diligently modified the structure of 
MDP to create various MDP derivatives to increase their immunodulatory property14. 
Studies have shown that some MDP derivatives are beneficial in treating cancer, as well 






For example, murabutide (MB, Figure 8) increases the antiviral and antitumor impacts of 
cytokines, such as IFN-α and IL-2. Studies have discovered that injecting MB together 
with IL-2 causes significant tumor inhibition with total tumor regression in more than 
70% of injected individuals45. Moreover, mifamurtide (Figure 5) is an example of many 
therapeutic drugs that require the collaboration of NOD2 to cure cancer46. The binding 
of mifamurtide to NOD2 activates white blood cells to fight against viral and bacterial 
infections47. In addition, mifamurtide has been used in combination with chemotherapy 
to treat osteosarcoma. 
 
1.6 NOD2 therapeutic concerns 
The NOD2 protein recognizes bacteria and stimulates the immune system to respond to 
an infection. When activated by certain substances released by bacteria, NOD2 
activates a protein complex known as the nuclear factor-kappa-B (NF-ĸB). The protein 
complex is responsible for controlling the activation of many genes. Some of these 
genes include those that control the immune responses and ones that control the 
inflammatory responses48. NOD2 also plays a critical role in autophagy, a self-
degradative process in which a cell eats its components. It is the primary catabolic 
mechanism that involves cell degradation through the action of lysosomes of 
unnecessary or unfunctional cellular components49. Therefore, the prime concern of 
stimulating NOD2 receptor is having over activating responses leading to unwanted 




2. OBJECTIVES OF THE PRESENT WORK 
Although MDP and its derivatives represent potential therapeutic agents, they are still 
under clinical investigation due to their drawbacks. Some of the downsides are poor 
penetration of macrophages, pyrogenicity, and inflammatory reaction. In this study, 
considerable focus was placed on synthesizing novel MDP analogues by modifying the 
dipeptide moiety.   
 
The MDP analogues are comprised of two building blocks: the carbohydrate moiety and 
the dipeptide moiety. In this research, a group of novel MDP analogues have been 
designed by (a) replacing the D-iso-glutamine (D-iso-Gln) with an aromatic amino acid, 
3,4-di-aminobenzoic acid (DABA), and (b) attaching a lipophilic chain of different length 
at the C-terminal of the dipeptide moiety. The objectives of this thesis are to complete 
the synthesis of a group of such novel MDP analogues for future biological studies.  
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3 RESULTS AND DISCUSSION 
 
3.1 Design of MDP analogues 
As mentioned earlier, MDP is involved in a critical signaling pathway of the innate 
immune system against microbial infections. Studies show that it displays anticancer 
activity as well as vaccine adjuvant activity50,51,52. However, there are several drawbacks 
associated with MDP − such as toxicity, hydrophilicity, and rapid elimination from the 
biological system − which prevent this molecule from being used in the clinic. Previously 
reported MDP analogues have incorporated modifications to both sugar and dipeptide 
residues, mainly to increase their lipophilicity and, thus, intracellular delivery. In this 
research, unique mimics of MDP are proposed in which the dipeptide part is modified. In 
particular, the D-iso-glutamine (D-iso-Gln) is replaced with an aromatic amino acid, 3,4-
di-aminobenzoic acid (DABA), and a lipophilic chain of different length is attached at the 
C-terminal of the dipeptide moiety. A significant advantage of these novel analogues is 
that DABA is structurally analogous to D-iso-Gln (Figure 11). Replacing D-iso-Gln is an 
attractive option for the synthesis of MDP analogues since D-iso-Gln is an expensive 
amino acid. Additionally, the aromatic ring in DABA enhances the stability of such MDP 
analogues (1 and 2, Figure 12) toward enzymes relative to the natural MDP bearing D-
iso-Gln. A substituent group (R) on the 4-amino group of DABA can bring structural 
variation to these analogues. R could be an alkyl group (proposed structure 1) or acyl 
substituent (structure 2). In mimic 3, the N-acetylmuramic acid moiety exists as the 
benzyl α-glycoside. According to Yang et al.25, benzyl glycosides of MDP derivatives 
show significant immunomodulating activity. Therefore, these benzyl glycosides can 
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potentially interact with NOD2 and display agonistic or antagonistic activity. Finally, the 
lipid chains were presented in analogues 4 – 9 to increase the lipophilicity of these 
molecules (Figure 13). 
 
Figure 11. Structure of muramyl dipeptide (MDP). 
 
 





Figure 13. Target lipophilic MDP mimics   
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3.2. Retrosynthetic analysis for the lipophilic MDP analogues 
Based on scheme 1, compounds 4 - 6 can be disconnected to give the sugar building 
block 10 and the dipeptide building blocks 11 - 13. The synthesis of compound 10 has 
been reported in the literature53,54,55. The dipeptide building blocks 11 - 13 could be 
broken down to more simple molecules: alkyl amines and compound 14. Furthermore, 
compound 14 can be disconnected to Boc-L-alanine and amino acid derivative 15 which 
can be prepared from the commercially available 4-amino-3-nitrobenzoic acid 16.  
Scheme 1. Retrosynthetic analysis of the lipophilic analogues 4 – 6. 
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3.3 Preparation of 4-amino-3-nitrobenzoic acid derivatives 
 
3.3.1 Protecting amino group 
3.2.1.1 Boc-group 
4-Amino-3-nitrobenzoic acid 16 is the starting material for the preparation of 3,4-
diaminobenzoic acid (DABA) building blocks. Forming an intermediate with a temporary 
protecting group at the 4-amino group of DABA is necessary in order to introduce a 
different R group at late stage of the synthesis. Therefore, different protecting groups 
were investigated. The tert-butyloxycarbonyl (Boc) is a general amino protecting group, 
and therefore 16 was first tried to react with Boc-anhydride in order to make 17 
(Scheme 2). Compound 17 was not formed under various sets of reaction conditions, as 
indicated by the absence of a carbon signal at around δ = 28 ppm in the 13C NMR 
spectrum of the isolated product. This carbon signal is indicative of the Boc-group. The 
results of these experiments indicate that the amino group in 16 is very unreactive.  
 




3.3.1.2 Troc-group  
Another common protecting group for amines is the 2,2,2-trichloroethoxycarbonyl (Troc) 
group. Treating 16 with 2,2,2-trichloroethoxyl chloroformate (Troc-Cl) and 
diisopropylethylamine (DIPEA) in different solvents offered the desired product 18 in low 
yields (Scheme 3 and Table 1). TLC indicated the formation of other side products; 
structure such as 19 might be formed during the reaction since Troc-Cl can potentially 
react with a carboxylic acid. The structures of these side products were not established.  
 
Scheme 3. Protecting the amine group on 16 by Troc-Cl.  
 
Table 1. Conditions and yields for the Troc protection reaction 
Solvents/ Reagents Temperature (oC)  Yield: 18 
Acetone/ DIPEA rt 10% 
EtOAc/ DIPEA 80 28% 
Toluene/ DIPEA 120 24% 
 
According to the results of the reaction in Scheme 3, the carboxyl group in 16 should be 
protected first before protecting the amino group. This strategy would prevent Troc-Cl 
from attacking the carboxyl group. Thus, compound 16 was treated with phenacyl 
bromide and triethylamine in dioxane to give 20 in 93% yield. After that, compound 20 
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was treated with Troc-Cl in the presence of DIPEA as an activator in toluene at 120 °C 
to give the desired protected product 21 in 71% yield. Reducing the nitro group in 21 by 
using Pd/C under H2 in CHCl3/MeOH (2:1) provided 22. Compound 22 was structurally 
not confirmed due to its instability. An attempt was nevertheless made to couple the 
reaction product with Boc-L-alanine under the coupling condition of HBTU and DIPEA in 
DMF (Scheme 4), but the anticipated product 23 was not isolated. It is unclear whether 
22 failed to form altogether or it was too short-lived to undergo coupling. Due to time 
constraint, the issues faced with this method were not further investigated. Instead, we 
switched our focus to preparing N-acetylated derivatives (See next section). However, 
putting a protecting group on the 4-amino group of 16 is still worth further study in order 
to prepare an advanced intermediate to access structures such as 1 (Figure 12) with a 
variable R group at that nitrogen atom. 
 
Scheme 4. Protecting strategy with Troc group  
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3.3.2 N-Acylation  
Here, the acyl group was introduced directly in the initial step. Successfully, both acetyl 
and butyryl groups were added to the amino group in 16.  Compound 16 was treated 
with acetic anhydride in acetic acid and sulfuric acid at 100 °C to form 24 in 98% yield. 
Under the same conditions and by using butyric anhydride, compound 25 was obtained 
in quantitative yield (Scheme 5). The present work focused on the synthesis of MDP 
mimics bearing an N-acetyl substituted aromatic amino acid residue. Therefore, 
compound 24 was subsequently used to form our target molecules while compound 25 
could be used in future studies to produce MDP mimics bearing an N-butyryl substituted 
aromatic amino acid residue.   
 
 





3.3.3 Attachment of lipids  
3.3.3.1 Lipidation of 16 
In order to reduce the number of protecting groups required, an alternative pathway was 
investigated by which the lipid chain would be added early on, so that it would also 
serve to block the carboxyl group from interfering with formation of other amide bonds. 
Compound 26 was prepared with an 81% yield by coupling compound 16 with 
hexadecyl amine in the presence of DIPEA and HBTU in DMF (Scheme 6). Compound 
26 was then treated with Troc-Cl and DIPEA in toluene to make 27 in 71% yield. 
Compound 27 could be used in the future to generate a general building block to access 
other MDP mimics with a variable R substituent on the amino group. 
 






3.3.3.2 Lipidation of 24 
Since we chose to converge on the synthesis of MDP mimics bearing an N-acetyl 
substituent on the aromatic ring, a lipidation reaction was applied to 24 using the 
general coupling conditions (Scheme 7). As a result, compound 28 was achieved with 
40% yield. Due to the solubility issue of compound 28, the purification was not an easy 
procedure.  
 
Scheme 7. Lipidation of compound 24 
 
3.4 Preparation of the dipeptide building blocks  
 
3.4.1 Metallic reduction of the nitro group  
The reduction of the nitro group in 28 was tried using two different sets of conditions. 
Compound 28 was treated with tin (Sn) in the HCl acidified MeOH and heated at 50 oC. 
TLC analysis of the reaction mixture indicated clear conversion of the starting material 
to a much more polar product, which was reasonably assumed to be the expected 
amine 29 in HCl salt form. A similar TLC profile was observed when the reaction was 
carried out using zinc powder (Zn) in ethanol and acetic acid at 70 oC. As the work-up 
procedure of these reactions, the reaction mixture was first treated with 1 M NaOH to 
adjust pH to ca. 5. Due to the chemical instability of 29 in free amine form and the large 
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amount of tin/zinc salt present in the reaction mixture, it was hard to isolate compound 
29 in pure form; therefore, we proceeded with the coupling of 29 to Boc-L-Ala-OH 
(Scheme 8). The desired product 13, however, was not obtained, possibly because a 
large amount of metal salts (SnCl2 or Zn(OAc)2) in the mixture interfered the reaction. 
Due to the complexity of the work-up procedure for the metal reduction of the nitro 
group, this reaction pathway was not continued.  
 
 




3.4.2 Activating Boc-L-Ala-OH 
An activated intermediate form of Boc-L-ala-OH (30) was prepared in quantitative yield 
by treating Boc-L-Ala-OH with N-hydroxy succinmide (NHS), N,N'-
dicyclohexylcarbodiimide (DCC) and CH2Cl2 (Scheme 9).  
 
 
Scheme 9. Preparation of the active form of Boc-L-Ala-OH.  
 
3.3.3 Preparation of building block 14  
The nitro group in 24 was reduced through catalytic hydrogenation using palladium on 
activated carbon (Pd-C) in MeOH under hydrogen atmosphere in a Schlenk apparatus, 
resulting in compound 31 which presents sensitivity toward air (Scheme 10). Next, 31 
was directly coupled to L-alanine in two approaches. As presented in Scheme 10, 
compound 31 and Boc-L-Ala-OH were dissolved in DMF along with coupling agents 
HBTU and DIPEA to form 14 in 35% yield over two steps. In the other approach, 31 and 
the activated alanine 30 were treated with DIPEA in DMF to generate 14 in 42% yield 
over two steps. So the reaction of 24 with the pre-activated alanine 30 provides slightly 




Scheme 10. Reducing the nitro group in 24 followed by coupling with L-alanine. 
 
3.3.4 Lipidation of the dipeptide derivative 14 
The lipid chains could be added to the dipeptide derivatives at this stage. Product 14 
was coupled to hexyl amine, dodecyl amine, and hexadecyl amine by the coupling 
condition of HBTU and DIPEA in DMF to afford 11, 12, and 13 in 83%, 59%, and 85% 




Scheme 11. Lipidation of the dipeptide derivative 14 
 
3.4 Preparation of MDP mimics 
 
3.4.1 N-Boc deprotection  
Following the general procedure to remove the protecting Boc-group, compounds 11 – 
14 were treated individually with trifluoracetic acid (TFA)/dichloromethane/water 
(45:50:5) (Scheme 12) to give 32 – 35, respectively, in quantitative yields. Compounds 






Scheme 12. The removal of the Boc-group. 
3.4.2 Activating the N-acetylmuramic acid 
Following known procedures53,54,55, compound 10 was prepared by my coworker Dr. 
Farooq Khan. Compound 10 was reacted with NHS and DCC in dry CH2Cl2 at 0° C to 
make 36 in quantitative yield (Scheme 13).  
 
Scheme 13.  Preparation of the activated sugar building block 36   
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3.4.3 Linking the carbohydrate moiety to the peptide residue  
The activated ester of N-acetylmuramic acid derivative 36 was dissolved in dry CH2Cl2 
and treated with amines 32, 33 and 34 separately. Compounds 37, 38 and 39 were 
obtained with 69%, 53%, and 71% yields, respectively (Scheme 14). The structures of 
37 – 39 were confirmed by NMR and MS data. 
 
Scheme 14. The preparation of intermediates 37, 38 and 39  
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3.5 Synthesis of the target MDP analogues 4 – 9  
Two different deprotection methods were employed in order to form the target 
analogues with lipid chains. The first group of analogues, 4 − 6, were synthesized using 
the general deprotection method, that is, by treating 37, 38 and 39 with Pd-C under 
hydrogen atmosphere in 1:1 THF/CH3OH in 40 to 69% yield. The other group of 
analogues 7 − 9, were obtained with 60–100% yield by dissolving, respectively, 37,38 
and 39 in TFA/CH2Cl2/H2O (45:50:5) at 0 °C to cleave the 4,6-O-benzylidene acetal 
group (Scheme 15). The structures of 4 – 9 were confirmed by NMR and MS spectral 
data.  




3.6 Preparation of the hydrophilic MDP analogues  
 
3.6.1 Retrosynthetic analysis of the hydrophilic MDP analogues 
As described for the lipophilic analogues, compound 2 can be disconnected to give the 
sugar building block 10 and the dipeptide building block 14 (Scheme 16). The synthetic 
methods for 10 and 14 have been described in the previous Sections 3.3.3 and 3.4.2.  
 
Scheme 16. The retrosynthetic analysis of mimic 2  
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3.6.2 Linking the carbohydrate derivative 36 to the dipeptide derivatives 35 
Compounds 35 and 36 were coupled in two different ways to give 40 (Scheme 17). In 
the first way, 40 was obtained by adding both 35 and 36 to DIPEA in dry CH2Cl2. In the 
second way, 40 was formed by employing sodium bicarbonate (NaHCO3) in 1:1 H2O/ 
dimethoxyethane (DME). Compound 40 was produced impurely through these two 
procedures and the subsequent purification procedure was very challenging according 
to TLC. For purification purpose, the carboxyl group of 40 was converted to a benzyl 
ester. In this step, the impure mixture of product 40 was reacted with benzyl bromide 
(C6H5CH2Br) in the presence of DIPEA in acetonitrile (CH3CN) to form 41 in 89% yield 




Scheme 17. Linking the carbohydrate derivative 36 to the dipeptide derivatives 35 
 
3.6.3 Attempt to synthesize the target analogues 2 and 3 
To form products 2 and 3, compound 41 was subjected, as a first try, to deprotection 
with Pd-C and H2 in 1:1 tetrahydrofuran (THF)/acetic acid (HOAc) to afford the target 
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molecule 2 in an impure mixture (5 mg, 38%). Alternatively, dissolving compound 41 in 
TFA/CH2Cl2/H2O (45:50:5) at 0 °C cleaved the 4,6-O-benzylidene acetal group and 
gave the intermediate 42 in 90% yield. Finally, the benzyl ester 42 was subjected to 
hydrolysis with 1 M lithium hydroxide (LiOH) and THF (1:2) (Scheme 18) to form 3 (5 
mg, 63%). The structures of both 2 and 3 were not characterized. However, there was 
not enough material of compound 41 and 42 for a second attempt. These reactions 
need to be repeated in order to provide enough pure materials for the structural 









Muramyl dipeptide is the smallest structure motif of peptidoglycan found in all types of 
bacteria. Scientists have discovered that muramyl dipeptide has immunostimulatory 
property that plays an important role as an adjuvant in vaccines. Muramyl dipeptide is a 
ligand for the NOD2 receptor, which activates innate immunity. The detection of the 
bioactive MDP activates the cytosolic pattern recognition receptor NOD2. NOD2 
activation plays a critical role in both innate and adaptive immune systems by producing 
an inflammatory immune response and releasing cytokines. Numerous investigations 
have focused on the structure activity relationship of MDP for activating the NOD2 
signaling pathway. Also, a great deal of work has been conducted with various synthetic 
MDP analogues. The goal of using these MDP analogues is not only to harness the 
beneficial immunostimulatory properties of MDP, but also to eliminate the toxic side effect 
associated with MDP.   
In the present study, a novel group of MDP analogues have been synthesized. In this 
case, the D-iso-glutamine is replaced by an aromatic amino acid that is attached to a lipid 
chain. This modification is thought to offer advantages in terms of chemical and enzymatic 
stability, as well as membrane permeability. The synthesis of the dipeptide component 
was started with N-acetylation of the commercially available 4-amino-3-nitrobenzoic acid, 
which is followed by a reduction of the nitro group, and then coupling with L-alanine to 
yield the critical dipeptide building block 14. Lipid chains of different length were coupled 
with 14 to form dipeptide building blocks 11 – 13. The reaction between the N-
acetylmuramic acid derivative 36 with the dipeptide analogues 11 – 14 provided protected 
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MDP analogues 37 – 40. Global deprotection of 37 – 39 using Pd/C as the catalyst in a 
hydrogen atmosphere resulted in the removal of both benzyl and benzylidene groups, 
providing the first set of MDP analogues 4 – 6. Treatment of 37 – 39 with TFA caused the 
cleavage of the 4,6-O-benzylidene group and gave the second set of MDP analogues 7 
– 9 as benzyl -glycosides of N-acetylmuramic acid derivatives. For the preparation of 
MDP analogues (2 and 3) without a lipid chain attached, compound 40 was converted to 
the benzyl ester 41. Global deprotection of 41 under catalytic hydrogenation resulted in 
MDP mimic 2, while treatment with TFA followed by LiOH provided MDP mimic 3. The 
structures of the synthesized MDP analogues 4 – 9 were characterized by 1H NMR, 13C 
NMR and MS spectral data while that of 2 and 3 were not characterized. 
 
5. FUTURE STUDIES 
The biological evaluation of MDP analogues has been left for future study due to lack of 
time. Therefore, the first goal of future studies should be concentrated on testing the 
activity and the safety of the lipophilic analogues 4 - 9. If these molecules work well as 
immunomodulatory agents, the use of muramyl peptide analogues at low and safe 
doses in combination with other drugs, including antibiotics and cytokines, might lead to 
another biological investigation. In terms of the biological studies, human monocyte 
cells (THP-1 monocytes) would be utilized to preliminarily test the immune stimulating 
ability of synthesized analogues. Cell counting would be performed using a 
hemocytometer, with viability being determined through the trypan blue cellular 
exclusion method. As preliminary studies, ICAM-1 induction and cytokines (including 
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TNF- and IL-6) will be measured to determine the immune-stimulating activity of the 
synthesized MDP analogues.  
 
From the synthesis point of view, adding protecting groups at the C- and N-terminals of 
the starting point (4-amino-3-nitobenzoic acid) in order to add a variety of R groups at 
these two positions is worth more investigation. For example, the preparation of building 
block 23 (Scheme 4) is worthy of reinvestigation. Compound 23 has an N-Troc 
protection group on the 4-amino group of the aromatic amino acid, which allows for the 
introduction of a variable substituent at that nitrogen at the late stage of the synthesis. In 
addition, the deprotection for getting the final hydrophilic mimics 2 and 3 needs to be 
repeated with different reaction conditions.  
 
It could also be possible to design new MDP analogues by replacing amide-linked lipids 
with ester-linked lipid chains, which could be more favorable in biological metabolism. If 
the present modified analogues present high ability to activate innate immunity, that 
would confirm that the the employed 3,4-diaminobenzoic acid (DABA) is a good 
replacement for D-iso-glutamine. New MDP analogues based on DABA, perhaps 




6 Experimental  
6.1 General methods 
TLC was performed on Silica Gel 60Å F254 (thickness 250 µm; Silicycle Inc., Canada) 
and detected by fluorescence (254 nm), followed by dipping into one of the staining 
reagents, 15% H2SO4 or Mostain reagent [ammonium molybdate ((NH4)6Mo7O24.4H2O, 
20 g) and cerium (IV) sulfate (Ce(SO4)2, 0.4 g) in 10% H2SO4 solution (400 ml)] and 
charring at ~ 120 °C. 
Flash column chromatography was performed on Silica Gel 60 (40 - 63 µm; Silicycle 
Inc., Canada). 1H NMR and 13C NMR spectra were recorded on a Varian Unity Inova 
500 MHz spectrometer. Tetramethylsilane (TMS, δ 0.00 ppm) or solvent peaks were 
used as internal standards for 1H and 13C NMR spectra. The chemical shifts were given 
in ppm and coupling contents in Hz. Multiplicity of proton signals is indicated as follows: 
s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), m (multiplet), br 
(broad), and approx. (approximate).  
All air and moisture sensitive reactions were performed under nitrogen atmosphere. All 
commercial reagents were used as supplied. Anhydrous solvents were dried according 
to literature procedures. Dichloromethane was distilled over calcium hydride, while THF 
was distilled over sodium. Anhydrous DMF was purchased from Sigma Aldrich. Optical 
rotations were measured with a PerkinElmer 241 Polarimeter at rt (20 - 22 °C). Mass 
spectra were obtained from a Biflex-IV MALDI linear/reflector instrument at Western 




6.2 2-Oxo-2-phenylethyl 4-amino-3-nitrobenzoate (20) 
 
A solution of compound 16 (1.03 g, 5.49 mmol) and triethylamine Et3N (0.76 ml, 7.51 
mmol) in dioxane (6 ml) was stirred at rt for 30 min. After that, phenacyl bromide (1.12 
g, 5.64 mmol) was added to the mixture and stirred at rt for 2 h. The solvent was 
removed in vacuo and the residue was dissolved with EtOAc (100 ml) and washed with 
H2O (10 ml x 2). The organic layer was dried over anhydrous Na2SO4 and concentrated 
under vacuum to give product 20 (1.587 g, 93%) as a yellow solid. Rf 0.35 (hexane/ethyl 
acetate, 2:1). 1H NMR (500 MHz, chloroform-d):δ 8.97 (d, J = 1.9 Hz, 1H), 8.07 (dd, J = 
8.7, 1.9 Hz, 1H), 8.04 – 7.90 (m, 2H), 7.63 (d, J = 7.5 Hz, 1H), 7.52 (t, J = 7.5 Hz, 2H), 
6.86 (d, J = 8.7 Hz, 1H), 5.58 (s, 2H). 13C NMR (126 MHz, chloroform-d): δ 192.01, 
164.38, 147.61, 136.11, 134.17, 134.02, 129.63, 128.94, 127.83, 118.57, 118.22, 66.50. 
 
6.3 2-Oxo-2-phenylethyl 3-nitro-4-(2,2,2-trichloroethoxycarbonyl)aminobenzoate (21) 
 
A solution of compound 20 (300 mg, 0.9997 mmol) and N,N-diisopropylethylamine 
(DIPEA, 0.68 ml, 5.261 mmol) in toluene (15 ml) was stirred at 120 °C. Then, 2,2,2-
trichloroethyl chloroformate (Troc-Cl) (0.52 ml, 2.454 mmol) was diluted in toluene (5 
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ml) and added dropwise over 45 mins to the stirring mixture. After stirring for two days 
at 120 °C, the solvent was removed in vacuo. The residue was subjected to a dry 
loading flash column chromatography (CH2Cl2/Hexane, 5:2) to give 21 (330 mg, 71%) 
as light yellow solid. Rf 0.47 (CH2Cl2/hexane, 5:2). 1H NMR (500 MHz, chloroform-d): δ 
10.35 (s, 1H), 9.04 (d, J = 7.4 Hz, 1H), 8.72 (d, J = 7.4 Hz, 1H), 8.49 – 8.36 (m, 1H), 
8.03 – 7.91 (m, 2H), 7.60 (d, J = 7.4 Hz, 1H), 7.64 – 7.52 (m, 2H), 4.90 (s, 2H), 4.76 (s, 
2H).13C NMR (126 MHz, chloroform-d): δ 191.39, 163.61, 153.15, 151.05, 138.28, 
136.87, 135.80, 134.07, 129.01, 128.25, 127.82, 124.33, 120.59, 94.50, 74.95, 66.91. 
 
6.4 4-Acetamido-3-nitrobenzoic acid (24) 
 
A solution of 16 (3.00 g, 16.471 mmol) in acetic anhydride (15.56 ml, 152.414 mmol) 
and acetic acid (20 ml) was stirred for 4 h at 110 °C. Then, sulfuric acid (3.5 ml) was 
added, and the solution was stirred for another 4 h at the same temperature. The 
mixture was then poured in a beaker containing ice. The precipitate was filtrated and 
washed three times with cold water to give 24 (3.68 g, 98%) as off-white to light yellow 
solid. Rf 0.25 (acetone/hexane, 4:3). 1H NMR (500 MHz, DMSO-d6): δ 13.46 (s, 1H), 
10.54 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 8.19 (dd, J = 8.5, 2.0 Hz, 1H), 7.82 (d, J = 8.5 
Hz, 1H), 2.12 (s, 3H).13C NMR (126 MHz, DMSO-d6): δ 168.82, 165.38, 141.23, 135.09, 
134.37, 126.78, 126.01, 124.56, 23.70. MS m/z calcd for C9H8N2O5: 224.043; found: 




6.5 4-Butyrylamino-3-nitrobenzoic acid (25) 
 
A solution of 16 (3.00 g, 16.471 mmol) in butyric anhydride (15.56 ml, 152.414 mmol) 
and acetic acid (20 ml) was stirred for 3 h at 90 °C. Then, sulfuric acid (3 ml) was 
added, and the solution was continued with stirring for 2 h at the same temperature. The 
mixture was then poured in a beaker containing ice. The precipitate was filtrated and 
washed three times with cold water to give 25 (3.68 g, quant.) as beige solid. Rf 0.18 
(ethyl acetate/hexane/MeOH, 3:3:0.2). 1H NMR (500 MHz, chloroform-d): δ 10.63 (s, 
1H), 9.01 (d, J = 9.0 Hz, 1H), 8.98 (d, J = 2.1 Hz, 1H), 8.33 (dd, J = 9.0, 2.1 Hz, 1H), 
2.53 (t, J = 7.4 Hz, 2H), 1.82 (t, J = 7.4 Hz, 2H), 1.05 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, chloroform-d): δ 172.76, 166.55, 138.39, 137.16, 135.91, 128.17, 125.83, 121.94, 
30.02, 19.02, 13.93. MS m/z calcd for C11H12N2O5: 252.23; found: 253.065 [M+H], 





6.6 4-Amino-N-hexadecyl-3-nitrobenzamide (26) 
 
Compound 16 (1.00 g, 5.49 mmol) was dissolved with hexadecyl amine (1.32g, 5.49 
mmol), HBTU (2.208 g, 5.819 mmol) and DIPEA (2.09 ml, 16.17 mmol) in DMF (10 ml) 
and the mixture was stirred at rt for 18 h. The solvent was removed in vacuo, and the 
residue was dissolved in 250 ml of CH2Cl2 and washed with NaHCO3 (25 ml x 3), then 
with H2O (50 ml x1). The organic layer was dried over anhydrous Na2SO4 and 
concentrated under vacuum. The resulting residue was subjected to flash column 
chromatography (CHCl3/MeOH, 4.5:0.5) to give 26 as a yellow solid (1.8 g, 81%). Rf 0.8 
(CHCl3/MeOH, 4.5:0.5), 1H NMR (500 MHz, chloroform-d): δ 8.47 (d, J = 2.1 Hz, 1H), 
7.90 (dd, J = 8.7, 2.1 Hz, 1H), 6.85 (d, J = 8.7 Hz, 1H), 6.28 (s, 2H), 5.95 (s, 1H), 3.44 
(td, J = 7.3, 5.7 Hz, 2H), 1.63 (m, 2H), 1.27 – 1.4 (m, 26H), 0.92 – 0.84 (m, 3H). 13C 
NMR (126 MHz, chloroform-d): δ 165.23, 146.44, 134.62, 124.68, 124.04, 119.01, 
45.14, 40.36, 31.99, 29.84, 29.74, 29.72, 29.70, 29.65, 29.60, 29.39, 27.11, 22.71, 
14.04. MS m/z calcd for C23H39N3O3: 405.29; found: 406.298 [M+H], 428.27 [M+Na ] 





6.7 N-Hexadecyl-3-nitro-4-(2,2,2-trichloroethoxycarbonyl)aminobenzamide (27) 
 
A solution of 26 (500 mg, 1.2318 mmol) and DIPEA (0.85 ml, 6.576 mmol) in toluene 
(10 ml) was stirred at 120 °C. Then, trichloroethyl chloroformate (Troc-Cl) (0.66 ml, 
3.128 mmol) was added dropwise over 30 min. The mixture was stirred for 16 h and the 
solvent was removed in vacuo. The residue was diluted in EtOAc (100 ml) and washed 
with 0.1 M HCl (15 ml x 1), NaHCO3 (20 ml x 1) and finally with H2O (20 ml x 1). The 
organic layer was dried over anhydrous Na2SO4 and concentrated under vacuum. The 
resulting residue was subjected to flash column chromatography (CHCl3:  
EtOAc/hexane,1:2) to give 27 (0.5 g, 71%) as a very light yellow solid. Rf 0.14 (CH2Cl2), 
1H NMR (500 MHz, chloroform-d): δ 10.22 (s, 1H), 8.69 – 8.63 (m, 2H), 8.09 (dd, J = 
9.0, 2.2 Hz, 1H), 6.12 (s, 1H), 4.88 (s, 2H), 3.47 (q, J = 6.8 Hz, 2H), 1.65 (q, J = 7.2 Hz, 
4H), 1.40 – 1.34 (m, 2H), 1.25 (s, 22H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
chloroform-d) δ 164.31, 151.15, 136.70, 135.78, 134.25, 129.55, 124.69, 120.87, 94.50, 
74.92, 40.44, 31.93, 31.59 29.71, 29.70, 29.68, 29.67, 29.65, 29.61, 29.60, 29.54, 
29.37, 29.31, 27.00, 22.70, 14.14. MS m/z calcd for C26H40Cl3N3O5: 579.97; found: 





6.8 4-Acetamido-N-hexadecyl-3-nitrobenzamide (28) 
 
A solution of 27 (700 mg, 3.029 mmol), and hexadecyl amine (800 mg, 3.313mmol) with 
DIPEA (1.05 ml, 8.123 mmol), and HBTU (1.14g, 3.0289 mmol) in DMF (25 ml) was 
stirred at rt. After stirring for two days, the solvent was removed in vacuo and the 
residue was dissolved with CHCl3 (70 ml) and washed with NaHCO3 (10 ml x 3), then 
with H2O (15 ml x1). The organic layer was dried over anhydrous Na2SO4 and 
concentrated under vacuum to give product 28 as a white solid (520 mg, 40 %). Another 
way to get compound 28 is to treat 26 in a similar procedure of forming 24. This 
pathway gave 28 in 89%. Rf 0.5 (chloroform/MeOH, 9:0.5), 1H NMR (500 MHz, 
chloroform-d): δ 10.47 (s, 1H), 8.89 (d, J = 8.9 Hz, 1H), 8.63 (d, J = 2.1 Hz, 1H), 8.03 
(dd, J = 8.9, 2.1 Hz, 1H), 6.17 (br s, 1H), 3.46 (td, J = 7.3, 5.8 Hz, 2H), 2.32 (s, 3H), 
1.71 – 1.58 (m, 2H), 1.25 (s, 26H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
chloroform-d): δ 169.15, 164.47, 137.04, 135.85 134.03, 129.47, 124.62, 121.99, 40.42, 
31.94, 29.70, 29.68, 29.67, 29.66, 29.60, 29.55, 29.32, 28.3827.00, 25.76, 22.71, 14.14. 






6.9 2,5-Dioxopyrrolidin-1-yl (S)-2-tert-butoxycarbonylaminopropanoate (30) 
 
A mixture of Boc-L-Ala-OH (1 g), N-hydroxy succinimide NHS (608 mg, 5.282 mmol), 
and N,N'-dicyclohexylcarbodiimide DCC (1.09 g, 5.282 mmol) in dry dichloromethane (5 
ml) was stirred at 0-21 °C for 16 h. The solids were filtered and washed with 2 ml of dry 
dichloromethane. The filtrate was concentrated under vacuum to yield 30 (1.48 g, 98%) 
as white solid. Compound 30 was used directly for the preparation of 14. 
 
6.10 4-Acetamido-3-aminobenzoic acid (31) 
 
To a solution of 24 (800 mg, 4.015 mmol) in methanol (30 ml) in 100 ml Schlenk flask,  
palladium on activated carbon (5%, 40 mg) was added under argon atmosphere. The 
mixture was stirred under hydrogen gas (1 bar, using balloon) at rt for 20 h. The mixture 
was filtered, the solid washed with MeOH (10 ml), and the filtrate concentrated to afford 
31 as a white solid (700 mg, crude). Rf 0.22 (diethyl ether/acetic acid, 2 : 0.15), 1H NMR 
(500 MHz, chloroform-d): δ 7.33 (d, J = 1.9 Hz, 1H), 7.28 – 7.27 (m, 1H), 7.17 (d, J = 
7.7 Hz, 1H), 2.03 (s, 3H). 13C NMR (126 MHz, chloroform-d): δ 170.05, 168.41, 140.398, 
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128.88.128.17, 124.18, 120.33, 118.72, 22.53. This product presented sensitivity toward 
air, so it was proceeded to the following step directly. 
 
6.11 4-Acetamido-3-[2-(S)- tert-butoxycarbonylamino]propamidobenzoic acid (14) 
 
To a solution of 31 (700 mg, crude) and 30 (1.54 g, 5.379 mmol) in 10 ml of dry DMF, 
DIPEA (2.51 ml, 19.342 mmol) was added, and the mixture was stirred under argon 
atmosphere at 55°C for 2 days.  The solvent was removed in vacuo, and the residue 
was diluted with dichloromethane (100 ml) and washed with 15% citric acid solution (20 
ml x 3). The organic layer was dried over anhydrous Na2SO4, and concentrated under 
vacuum. The residue was subjected to flash column chromatography 
(CHCl3/MeOH/AcOH, 5:0.5:0.1) to give compound 14 (550 mg, 42% over 2 steps) as a 
beige solid. Rf 0.43 (CHCl3/MeOH/AcOH, 5:0.5:0.1), [α]D22 -6.6o (C 1.0, MeOH). 1H NMR 
(500 MHz, DMSO-d6): δ 9.55 (s, 1H), 9.37 (s, 1H), 8.02 (s, 1H), 7.81 (d, J = 8.5 Hz, 1H), 
7.76 – 7.71 (m, 1H), 7.35 (d, J = 8.5 Hz, 1H),4.10 (m, 1H) 2.13 (s, 3H), 1.40 (s, 9H), 
1.29 (d, J = 7.1 Hz, 3H), 13C NMR (126 MHz, DMSO-d6): δ 172.88, 172.67, 169.59, 
167.20, 156.16, 136.16, 129.45, 127.20, 127.12, 123.41, 79.01, 51.09, 45.00, 28.63, 
24.14, 21.52, 17.72. MS m/z calcd for C17H23N3O6: 365.158; found: 366.158 [M+H], 




6.12 4-Acetamido-3-[2-(S)-tert-butoxycarbonylamino]propanamido-N-hexylbenzamide  
(11) 
 
To a solution of compound 14 (300 mg, crude) and hexylamine (1.60 ml, 2.1416 mmol) 
in DMF (10 ml), HBTU (620 mg, 1.634 mmol) and DIPEA  (0.57 ml, 4.410 mmol) were 
added. After starring at rt for 16 h, the solvent was removed in vacuo. The residue was 
diluted in dichloromethane (100 ml) and washed with NaHCO3 (20 ml x 3) and then with 
H2O (25 ml x 1). The organic layer was dried over anhydrous Na2SO4 and concentrated 
under vacuum. The residue was subjected to flash column chromatography 
(CHCl3/MeOH, 5:0.5) and then further purified with second flash column 
chromatography (ethyl acetate/ hexane/ MeOH, 2:2:1.5) to give compound 11 (300 mg, 
83%) as beige solid. Rf 0.43 (ethyl acetate/ hexane/ MeOH, 2:2:1.5), [α]D22 - 24.9 (C 1.0, 
CHCl3). 1H NMR (500 MHz, chloroform-d): δ 9.03 (s, 1H), 8.89 (s, 1H), 7.61 (s, 1H), 
7.49 (d, J = 8.2 Hz, 1H), 7.31 (s, 1H), 7.06 (s, 1H), 5.77 (s, 1H), 4.17 (m, 1H), 3.34 (t, J 
= 6.6 Hz, 2H), 2.15 (s, 3H), 1.57 (q, J = 7.0 Hz, 3H), 1.42 (s, 9H), 1.36 – 1.08 (m, 8H), 
0.90 (m, 3H).13C NMR (126 MHz, chloroform-d): δ 173.08, 170.09, 167.06, 155.93, 
134.77, 131.37, 128.32, , 124.96, 123.42, 80.08, 51.04, 40.28, 39.45, 31.55, 31.45, 
29.66, 28.38, 28.32, 26.51, 23.89, 22.53, 17.78, 14.00. MS m/z calcd for C23H36N4O5: 







In a similar way as described for the preparation of 11, to a solution of compound 14 
(270 mg, crude) and decylamine (0.68 ml, 4.348 mmol) in DMF (5 ml), HBTU (1.73 g, 
4.5595 mmol) and DIPEA (1.59 ml, 12.3017 mmol) were added to give 12 (220 mg, 
59%) as beige product. Rf 0.28 (CHCl3/ MeOH, 5.5:0.5), [α]D22 - 8.6 (C 1.0, CHCl3/ 
MeOH 1:1). 1H NMR (500 MHz, chloroform-d): δ 9.04 (s, 1H), 8.82 (s, 1H), 7.58 (d, J = 
8.4 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 6.58 (s, 1H), 5.61 (s, 1H), 4.21 (m, 1H), 3.36 (m, 
2H), 2.18 (s, 3H), 1.60 (m, 2H), 1.45 (s, 9H), 1.35 (d, J = 7.0 Hz, 3H), 1.33 – 1.19 (m, 
14H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, chloroform-d): δ 173.04, 172.08, 
170.07, 167.10, 155.94, 134.79, 131.66, 128.70, 125.08. 123.65, 80.20, 51.30, 40.08, 
31.92, 29.57, 29.43, 28.44, 28.42, 27.06, 23.96, 23.24, 22.67, 17.99, 14.06. MS m/z 
calcd for C27H44N4O5: 504.33; found: 527.32 [M+Na] 
 
6.14 4-Acetamido-3-[2-(S)-tert-butoxycarbonylamino]propanamido-N-




In a similar way as described for the preparation of 11, to a solution of compound 14 
(200 mg, crude) and hexadecyl amine (123 mg, 0.5466 mmol) in DMF (5 ml), HBTU 
(414 mg, 1.0911 mmol) and DIPEA (0.38 ml, 2.9400 mmol) were added to give 13 (275 
mg, 85%) as beige product. Rf 0.85 (ethyl acetate/hexane/MeOH, 2:2:1.5), [α]D22 + 8.2 
(C 1.0, CHCl3/MeOH 1:1) 1H NMR (500 MHz, chloroform-d): δ 8.91 (s, 1H), 8.81 (s, 1H), 
7.60 (d, J = 8.3 Hz, 1H), 7.45 (s, 1H), 7.34 (dd, J = 8.3, 2.0 Hz, 1H), 6.79 (t, J = 5.8 Hz, 
1H), 5.63 – 5.59 (m, 1H), 4.19 (m, 1H), 3.37 (m, 2H), 2.19 (s, 3H), 1.60 (m, 2H), 1.46 (s, 
9H), 1.37 (d, J = 6.8 Hz, 3H), 1.26 (br s, 26H), 0.88 (t, J = 6.8 Hz, 3H).13C NMR (126 
MHz, chloroform-d): δ 173.09, 170.22, 167.17, 156.07, 143.93, 131.53, 128,47, 125.30, 
124.99, 123.58, 51.18, 40.42, 32.03, 29.83, 29.80, 29.78, 29.76, 29.68, 29.66, 29.53, 
29.48, 29.42, 28.46, 27.23, 22.80, 14.24. MS m/z calcd for C33H56N4O5: 588.425; found: 
611.39 [M+Na]. 
 
6.15 4-Acetamido-3-[(S)-2-aminopropanamido]-N-hexylbenzamide (32) 
 
A solution of 11 (300 mg, 0.6688 mmol) in mixture of TFA/Dichloromethane (1:1) was 
stirred at 0 - 21 °C for 16 h. The solvent was removed in vacuo, and the residue was 
dissolved with CH2Cl2 (70 ml) and washed with NaHCO3 (10 ml x 3), then with H2O (15 
ml x1). The organic layer was dried over anhydrous Na2SO4 and concentrated under 
vacuum to give the free amine product 32 (213 mg, 91%) as white solid. Compound 32 
was used directly in the next coupling reaction.  
58 
 
6.16 4-Acetamido-3-[(S)-2-aminopropanamido]-N-decylbenzamide (33) 
 
 
In a similar way as described for the preparation of 32, a solution of 12 (230 mg, 
0.4557mmol) in mixture of TFA/dichloromethane (1:1) was stirred at 0 - 21 °C for 16 h. 
Then, the solvent was removed in vacuo, and the residue was dissolved with CH2Cl2 (70 
ml) and washed with NaHCO3 (10 ml x 3), then with H2O (15 ml x1). The organic layer 
was dried over anhydrous Na2SO4 and concentrated under vacuum to give the amine 
33 (220 mg, quant) as white solid. Compound 33 was used directly in the next coupling 
reaction.  
 
6.17 4-Acetamido-3-[(S)-2-aminopropanamido]-N-hexadecylbenzamide (34) 
 
In a similar way as described for the preparation of 32, a solution of 13 (100 mg, 
0.170mmol) in mixture of TFA/dichloromethane (1:1) was stirred at 0 - 21 °C for 16 h. 
Then, the solvent was removed in vacuo, and the residue was dissolved with CH2Cl2 (70 
ml) and washed with NaHCO3 (10 ml x 3), then with H2O (15 ml x1). The organic layer 
was dried over anhydrous Na2SO4 and concentrated under vacuum to give the 
intermediate 34 (140 mg, quant) as white solid. Compound 34 was used directly in the 




6.18 4-Acetamido-3-[(S)-2-aminopropanamido]benzoic acid (35) 
 
In a similar way as described for the preparation of 32, a solution of 14 (120 mg, 0.328 
mmol) in mixture of TFA/dichloromethane (1:1) was stirred at 0 - 21 °C for 16 h. Then, 
the solvents were removed in vacuo to give the intermediate 35 (140 mg, crude) as 





A mixture of 1053,54,55(1.13 g, 2.397mmol), N-hydroxy succinimide (NHS) (303 mg, 2.637 
mmol), and N,N'-dicyclohexylcarbodiimide (DCC) (521 mg, 2.517 mmol) in dry THF (30 
ml) was stirred at 0-21 °C for 16 h. The solid was filtered and washed with 2 ml of dry 
dichloromethane. The filtrate was concentrated in vacuo to afford 36 as white solid (1.13 
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To a solution of 32 (213 mg, 0.611 mmol) in dry dichloromethane (5 ml), 36 (347 mg, 
0.611 mmol) was added. The mixture was stirred under argon gas at rt for 24 hs. The 
solvent was then removed in vacuo. The residue was purified by flash column 
chromatography (CHCl3/MeOH, 3:0.25) to afford 37 (260 mg, 53%) as white solid. Rf 
0.49 (CHCl3/MeOH, 3:0.25); [α]D22 + 42.7 (C 1.0, CHCl3/MeOH, 1:1). 1H NMR (500 
MHz, DMSO-d6): δ 9.63 (s, 1H), 9.29 (s, 1H), 8.41 (t, J = 5.7 Hz, 1H), 8.20 (d, J = 8.3 
Hz, 1H), 7.91 (s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.72 (d, J = 2.1Hz, 1H), 7.65 (dd, J = 8.3, 
2.1 Hz, 1H), 7.48 – 7.24 (m, 10H), 5.70 (s, 1H), 4.89 (s, 1H), 4.71 (d, J = 12.4 Hz, 1H), 
4.51 (d, J = 12.4 Hz, 1H), 4.40 (q, J = 6.6 Hz, 1H), 4.32 – 4.21 (m, 1H), 4.21 – 4.13 (m, 
1H), 4.05 (td, J = 9.0, 8.6, 3.6 Hz, 1H), 3.83 – 3.70 (m, 4H), 3.21 (m, 2H), 2.07 (s, 3H), 
1.81 (s, 3H), 1.49 (m, 2H), 1.37 (d, J = 7.0 Hz, 3H), 1.27 (br s, 9H), 0.91 – 0.81 (m, 3H). 
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13C NMR (126 MHz, DMSO-d6): δ 173.10, 171.79, 170.22 169.42, 165.62, 138.05, 
137.99, 134.92, 131.00, 129.27, 129.00, 128.74, 128.61, 128.23, 128.11, 126.37, 
125.47, 124.92, 123.12, 100.79, 97.47, 81.25, 77.32, 76.64, 69.27, 68.37, 63.36, 53.64, 
49.52, 46.68, 45.12, 31.52, 29.58, 26.65, 24.19, 23.06, 22.56, 19.25, 18.16, 14.43. MS 





In a similar way as described for the preparation of 37, to a solution of 33 (200 mg, 
0.495 mmol) in dry dichloromethane (5 ml), 36 (281 mg, 0. 495 mmol) was added. The 
residue was purified by flash column chromatography (CHCl3/MeOH, 5:1) to afford 38 
(290 mg, 69%) as white solid. Rf 0.53 (CHCl3/MeOH, 5:1); [α]D22 + 82.6 (C 1.0, 
CHCl3/MeOH, 1:1), 1H NMR (500 MHz, DMSO-d6): δ 9.60 (s, 1H), 9.26 (s, 1H), 8.39 (t, 
J = 5.7 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 7.90 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.71 (d, 
J = 5.7 Hz, 1H), 7.64 (dd, J = 8.4, 2.1 Hz, 1H), 7.46 – 7.21 (m, 10H), 5.69 (s, 1H), 4.88 
(s, 1H), 4.70 (d, J = 12.4 Hz, 1H), 4.51 (d, J = 12.4 Hz, 1H), 4.38 (m, 1H), 4.25 (q, J = 
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7.1 Hz, 1H), 4.17 (dd, J = 9.4, 3.4 Hz, 1H), 4.07 – 3.99 (m, 1H), 3.80 – 3.69 (m, 4H), 
3.21 (q, J = 6.8 Hz, 2H), 2.06 (s, 3H), 1.78 (s, 3H), 1.45 (m, 2H), 1.36 (d, J = 7.1 Hz, 
3H), 1.30 – 1.19 (m, 17H), 0.84 (m, 3H). 13C NMR (126 MHz, DMSO-d6) δ 173.18, 
171.83, 170.36, 169.57, 165.70, 138.01, 137.95, 131.02, 129.29, 129.04, 128.74, 
128.61, 128.22, 128.12, 126.87, 126.36, 100.80, 97.42, 81.21, 77.31, 76.65, 69.27, 
68.42, 63.36, 53.61, 49.54, 31.76, 29.55, 29.46, 29.43, 29.25, 29.17, 26.93, 26.90, 
24.14, 23.02, 22.57, 19.22, 18.06, 14.44. MS m/z calcd for C47H63N5O10: 857.457; 





In a similar way as described for the preparation of 37, to a solution of 34 (86 mg, 0.205 
mmol) in dry dichloromethane (5 ml), compound 36 (97 mg, 0. 205 mmol) was added. 
The residue was purified by flash column chromatography (CHCl3/MeOH/AcOH, 
5:1:0.2) to afford 39 (120 mg, 71%) as white solid. Rf 0.34 (CHCl3/MeOH/AcOH, 
5:1:0.2); [α]D22 + 23.6 (C 1.0, CHCl3/MeOH,1:1) 1H NMR (500 MHz, DMSO-d6): δ 7.81 
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(d, J = 8.5 Hz, 1H), 7.70 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.49 (m, 2H), 7.38 – 7.31 (m, 
8H), 5.56 (s, 1H), 4.91 (d, J = 3.6 Hz, 1H), 4.72 (d, J = 11.7 Hz, 1H), 4.49 (d, J = 11.7 
Hz, 1H), 4.31 (m, 1H), 4.25 (dd, J = 10.3, 4.8 Hz, 1H), 4.09 (q, J = 6.8 Hz, 1H), 3.88 (m, 
1H), 3.81 – 3.72 (m, 2H), 3.66 (t, J = 9.2 Hz, 2H), 3.37 (t, J = 7.2 Hz, 2H), 2.04 (s, 3H), 
1.87 (s, 3H), 1.59 (m, 2H), 1.52 (d, J = 7.1 Hz, 3H), 1.39 (d, J = 6.8 Hz, 3H), 1.26 (br s, 
26H), 0.85 (m, 3H). 13C NMR (126 MHz, DMSO-d6) δ 173.10, 171.79, 170.22, 169.42, 
165.62, 138.05, 137.99, 134.92, 131.00, 129.27, 129.00, 128.74, 128.61, 128.23, 
128.11, 126.37, 125.47, 124.92, 123.12, 100.79, 97.47, 81.25, 77.32, 76.64, 69.27, 
68.37, 63.36, 53.64, 49.52, 46.68, 45.12, 45.01, 45.00, 31.52, 29.58, 26.65, 24.19, 




D-glucopyranos-3-O-yl)-propanamido]-propanamido}-benzoic acid (40) 
 
To a solution of 35 (69 mg, 0.261mmol) and 36 (114mg, 0.201 mmol) in DMF (5 ml), 
DIPEA (0.36ml, 2.785 mmol) was added, and the mixture was stirred at rt for 3 days. 
The solvent was removed in vacuo. The residue was subjected to dry loading flash 
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column chromatography (CHCl3/MeOH/AcOH, 5:0.5:0.1) to give product 40 (100 mg) 
which was slightly impure. For structure characterization, impure product 40 was 





A solution of the impure product 40 (100 mg, crude), benzyl bromide (78 mg, 0.456 
mmol), and DIPEA (0.23 ml, 1.779 mmol) in acetonitrile (3 ml) was stirred at rt for 16 h. 
The solvent was removed in vacuo. The residue was subjected to flash column 
chromatography (CHCl3/MeOH, 5:0.2, then 5:0.7) to give product 41 (90 mg, 89% over 
two steps). Rf 0.22 (CHCl3/MeOH, 5:0.2); [α]D22 + 24 (C 1.0, MeOH); 1H NMR (500 MHz, 
chloroform-d): δ 8.02 (s, 1H), 7.99 (d, J = 8.6 Hz, 1H), 7.94 (dd, J = 8.6, 2.0 Hz, 1H), 
7.49 – 7.31 (m, 15H), 5.58 (s, 1H), 5.33 (s, 2H), 4.91 (d, J = 3.7 Hz, 1H), 4.72 (d, J = 
11.7 Hz, 1H), 4.50 (d, J = 11.7 Hz, 1H), 4.35 – 4.20 (m, 4H), 4.11 (m, 1H), 3.95 – 3.88 
(m, 1H), 3.80 (dt, J = 10.4, 5.3 Hz, 1H), 3.68 (t, J = 10.4 Hz, 1H), 2.19 (s, 3H), 1.87 (s, 
3H), 1.26 (d, J = 7.0 Hz), 1.38 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, chloroform-
d/methanol-d4, 2:1): δ 179.08, 174.60, 172.26, 172.09, 170.92, 166.08, 137.24, 137.07, 
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136.97,136.02, 129.34, 128.78, 128.61, 128.50, 128.39, 128.01, 127.85 126.58, 126.51, 
126.14, 123.34, 101.73, 97.58, 81.58, 70.25, 69.04, 67.13, 63.36, 62.64, 59.82, 53.47, 
46.73, 45.80, 45.28, 37.28, 23.96, 22.90, 22.71, 19.08, 17.18, 14.20. MS m/z calcd for 





A solution of 41 (24 mg, 0.0297 mmol) in a mixture of dichloromethane (3 mL), TFA 
(2.75), and H2O (0.25 ml ) was stirred at 0 °C for 1 h. The solvents were then removed 
in vacuo. The residue was subjected to flash column chromatography 
(CH2Cl2/MeOH/H2O, 5:0.5:0.1, then 5:2:0.1) to afford 42 (20 mg, 94%) as white solid. Rf 
0.07 (CH2Cl2/MeOH, 5:0.5:); [α]D22 + 15.00 (C 0.5, CHCl3/MeOH, 1:1). 1H NMR (500 
MHz, methanol-d4): δ 8.07 (s, 1H), 7.93 (s, 1H), 7.66 (t, J = 3.1 Hz, 1H), 7.45 (s, 8H), 
7.36 – 7.21 (m, 2H), 5.33 (s, 2H), 4.85 (d, J = 3.5 Hz, 1H), 4.68 (d, J = 11.8 Hz, 1H), 
4.46 (d, J = 11.8 Hz, 1H), 4.24 (q, J = 6.7 Hz, 1H), 4.07 (dd, J = 10.5, 3.6 Hz, 1H), 3.79 
(m, 2H), 3.77 – 3.69 (m, 3H), 3.68 – 3.54 (m, 3H), 2.23 (s, 3H), 1.87 (s, 3H), 1.52 (d, J = 
7.1 Hz, 3H), 1.39 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, chloroform- methanol-d4) δ 
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175.02, 172.76, 171.93, 171.02, 166.09, 137.22, 136.16, 128.83, 128.73, 128.62, 
128.54, 128.42,128.39, 128.33, 128.00,126.86, 123.44, 97.14, 79.85, 72.58, 70.01, 
69.94, 67.15, 62.64, 61.93, 59.94, 53.33, 46.84, 45.88, 41.41, 32.14, 29.71, 23.88, 
22.80 18.76, 17.14, 14.10. MS m/z calcd for C37H44N4O11: 720.30; found: 721.33 [M+H], 
and 743.32 [M+Na]. 
 
6.26 4-Acetamido-3-{(S)-2-[(R)-2-(2-acetamido-β-D-glucopyranos-3-O-yl)-
propanamido]-propanamido}-benzoic acid (2) 
 
To a solution of 41 (20 mg, 0.0247mmol) in a mixture of THF/ AcOH 1:1, Pd-C (10%, 20 
mg) was added. The mixture was stirred under hydrogen gas with bubbling technique 
for a week. The mixture was filtrated, and the solid washed with acetic acid (5 ml x 2). 
The filtrate was concentrated by vacuum. The residue was subjected to purification by 
flash column chromatography (CHCl3/MeOH/H2O, 5:1:0.1) to afford 2 (5mg, 38%) as 
white solid. Rf 0.1 (chloroform/methanol, 5:1). Compound 2 was not pure and therefore 





propanamido]-propanamido}benzoic acid (3)  
 
A solution of 41 (10 mg, 0.013 mmol) was dissolved in THF (2 ml) and aqueous 1 M 
LiOH solution (1 ml) was added. The mixture was stirred at rt for 16 h. The mixture was 
neutralized by adding strong acidic ion-exchange resin (Amberlite IR-120H, H+ form). 
The resin was filtrated and the filtrate concentrated in vacuo. The residue was then 
subjected to purification through reversed-phase cartridge filtration to yield 3 (5 mg, 
63%) as light beige product. Rf 0.1(dichloromethane/methanol, 4:1) Compound 3 was 







To a solution of 37 (35 mg, 0.044 mmol) in a mixture of THF-AcOH (1:1, 40 ml), Pd-C 
(10%, 70 mg) was added. The mixture was stirred under hydrogen gas for a week. The 
mixture was filtrated, and the solid washed with acetic acid (5 ml, x 2) The solvents 
were removed under vacuum. The residue was purified by flash column 
chromatography (CHCl3/MeOH/H2O, 5:1:0.1) to afford 4 (27 mg, 69%) as white solid. 
Compound 4 was obtained as an anomeric mixture with  ratio of approximately 10:1. 
Rf 0.12 (CHCl3/MeOH 5:1), [α]D22 + 10.2 (C 1.0, CHCl3/MeOH, 1:1). 1H NMR (500 MHz, 
methanol-d4) for the -isomer: δ 7.91 (s, 1H), 7.86 (dd, J = 8.6, 2.1 Hz, 1H), 7.71 (dd, J 
= 8.6, 2.1 Hz, 1H), 5.11 (d, J = 3.5 Hz, 1H), 4.43 (q, J = 7.1 Hz, 1H), 4.38 – 4.35 (m, 
1H), 3.99 (dd, J = 10.5, 3.5 Hz, 1H), 3.83 – 3.80 (m, 1H), 3.74 – 3.71 (m, 1H), 3.55 – 
3.47 (m, 1H), 3.40 – 3.36 (m, 4H), 2.26 (s, 3H), 1.94 (s, 3H), 1.68 – 1.61 (m, 2H), 1.55 
(d, J = 7.1 Hz, 3H), 1.43 (d, J = 7.0 Hz, 3H), 1.41 – 1.32 (m, 6H), 1.00 – 0.91 (m, 3H). 
13C NMR (126 MHz, methanol-d4) for the -isomer: δ 176.62, 174.33, 173.59, 172.59, 
169.10, 132.94, 130.25, 162.71, 126.62, 124.88, 92.83, 81.18, 78.60, 73.40, 71.48, 
63.93, 62.89, 60.50, 58.29, 55.47, 41.28, 32.85, 30.61, 27.93, 23.78, 23.03, 19.60, 








In a similar way as described for the preparation of 4, to a solution of 38 (90 mg, 0.105 
mmol) in a mixture of THF/AcOH (1:1, 60 ml), Pd-C (10%, 80 mg) was added. The 
mixture was stirred under hydrogen gas at 35°C for eight days. The solvents were 
removed in vacuum. The residue was purified by flash column chromatography 
(CHCl3/MeOH/H2O, 5:1:0.2) to afford 5 (22 mg, 31%) as white solid. Compound 5 was 
obtained as an anomeric mixture with  ratio of approximately 3:1. Rf  0.12 
(CHCl3/MeOH, 5:1).  [α]D22 +12 (C 0.25, CHCl3/MeOH, 1:1). 1H NMR (500 MHz, 
methanol-d4): δ 8.05 – 7.50 (m, 3H), 5.14 (d, 3.6 Hz, 1H, H-1 for the -isomer), 4.00 
(dd, J = 10.4, 3.6 Hz, 1H), 3.87 (m, 1H), 3.82 (m, 1H), 3.78 – 3.66 (m, 4H), 3.56 – 3.46 
(m, 1H), 3.37 (m, 2H), 2.24 (s, 3H), 1.98 (s, 3/4 H), 1.96 (s, 9/4H ), 1.63 (m, 2H), 1.53 
(d, J = 7.0 Hz, 3H), 1.43 (d, J = 6.7 Hz, 3H), 1.35 – 1.21 (m, 14H), 0.89 (m, 3H). 13C 
NMR (126 MHz, methanol-d4): δ 174.94, 172.61, 171.90, 167.63, 167.17, 132.88, 
128.44, 125.60, 124.86,122.30, 91.40, 71.65, 70.18, 62.37, 59.46, 55.87, 53.70, 46.43, 
45.00, 40.12, 31.73, 26.92, 22.55, 22.40,18.41, 16.76, 13.64. MS m/z calcd for 






In a similar way as described for the preparation of 4, to a solution of 39 (50 mg, 0.0546 
mmol) in a mixture of THF/AcOH (1:1, 40 ml), Pd-C (10%, 45 mg) was added. The 
mixture was stirred under hydrogen gas for eight days. The solvents were removed by 
vacuum. The residue was purified by flash column chromatography (CHCl3/MeOH/H2O, 
5:1:0.1) to afford 6 (26 mg, 63%) as an anomeric mixture ( = ~ 6:1) as white solid. Rf 
0.18 (CHCl3/MeOH 5:1). [α]D22 + 15.7 (C 1.0, CHCl3/MeOH, 1:1). 1H NMR (500 MHz, 
methanol-d4) for the -isomer): δ 7.86 (s, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.5 
Hz, 1H), 5.12 (s, 1H), 4.45 – 4.27 (m, 3H), 3.99 (dd, J = 10.4, 2.1 Hz, 1H), 3.82 (m, 2H), 
3.75 – 3.72 (m, 4H), 3.68 (m, 1H), 3.55 – 3.44 (m, 1H), 3.41 – 3.33 (m, 2H), 2.25 (s, 
3H), 1.94 (s, 3H), 1.62 (m, 2H), 1.53 (d, J = 7.2 Hz, 3H), 1.43 (d, J = 6.8 Hz, 3H), 1.27 
(s, 26H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, methanol-d4): δ 174.99 172.74, 
172.05, 171.12, 167.65, 164.76, 159.86, 134.73, 131.46, 128.40, 125.52, 125.07, 
123.42, 91.31, 71.72, 69.84, 62.42, 61.49, 58.06, 56.40, 53.80, 52.49, 51.08, 46.30, 
45.43 40.01, 31.77, 29.51, 29.48, 29.44, 29.23, 28.8926.90, 23.01, 22.48, 22.01 18.30, 







A solution of 37(27 mg, 0.03366 mmol) in a mixture of dichloromethane (3 ml), TFA 
(2.75 ml) and H2O (0.25 ml) was stirred at 0 °C for 1 h. The solvents were then removed 
in vacuo. The residue was subjected to flash column chromatography 
(CH2Cl2/MeOH/H2O, 5:0.5:0.1) to afford 7 (24 mg, quant) as white solid. Rf  0.15 
(CH2Cl2/MeOH/H2O, 5:0.5:0.1); [α]D22 + 48.8 (C 1.0, MeOH). 1H NMR (500 MHz, 
methanol-d4): δ 8.10 (d, J = 2.1 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.86 (dd, J = 8.5, 2.1 
Hz, 1H), 7.56 – 7.40 (m, 5H), 5.01 (d, J = 3.6 Hz, 1H), 4.67 (d, J = 10.6 Hz, 1H), 4.59 (t, 
J = 10.6 Hz, 1H), 4.55 – 4.49 (m, 2H), 4.19 (dd, J = 10.6, 3.6 Hz, 1H), 4.05 – 3.96 (m, 
1H), 3.72 – 3.62 (m, 1H), 3.55 – 3.47 (m, 4H), 2.38 (s, 3H), 2.04 (s, 3H), 1.84 – 1.73 (m, 
2H), 1.68 (d, J = 7.1 Hz, 3H), 1.59 (d, J = 6.7 Hz, 2H), 1.54 – 1.44 (m, 6H), 1.12 – 1.03 
(m, 3H). 13C NMR (126 MHz, methanol-d4): δ 174.98, 172.73, 171.97, 171.06, 167.50, 
137.45, 134.75, 131.52, 128.00, 127.96, 127.49, 125.11, 125.03, 123.42, 96.18, 79.68, 
77.08, 72.84, 70.04, 68.86, 62.38, 61.22, 58.11, 56.47, 53.33, 49.93, 39.74, 31.28, 
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29.05, 26.36, 22.46, 22.20, 21.42, 18.10, 16.20, 12.93. MS m/z calcd for C36H51N5O10: 





In a similar way as described for the preparation of 7, a solution of 38 (98 mg, 0.1143 
mmol) in a mixture of dichloromethane (3 ml), TFA (2.75 ml) and H2O (0.25 ml) was 
stirred at 0 °C for 1 h. The solvents were then removed in vacuo. The residue was 
subjected to flash column chromatography (CH2Cl2/MeOH/H2O, 5:1:0.1) to afford 8 (45 
mg, 51%) as white solid. Rf 0.47 (CH2Cl2/MeOH/H2O, 5:1); [α]D22 + 26.2 (C 1.0, 
CHCl3MeOH,1:1). 1H NMR (500 MHz, Methanol-d4): δ 7.95 (d, J = 2.1 Hz, 1H), 7.83 (d, 
J = 8.5 Hz, 1H), 7.71 (dd, J = 8.5, 2.1 Hz, 1H), 7.40 – 7.23 (m, 5H), 4.84 (d, J = 3.6 Hz, 
1H), 4.71 (d, J = 11.7 Hz, 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.44 – 4.33 (m, 3H), 4.02 (dd, 
J = 10.6, 3.6 Hz, 1H), 3.84 (dd, J = 10.6, 2.0 Hz, 1H), 3.57 – 3.48 (m, 1H), 3.41 – 3.29 
(m, 4H), 2.23 (s, 3H), 1.87 (s, 3H), 1.61 (m, 2H), 1.53 (d, J = 7.1 Hz, 3H), 1.42 (d, J = 
6.8 Hz, 3H), 1.36 – 1.24 (m, 14H), 0.92 (t, J = 6.8 Hz, 3H).13C NMR (126 MHz, 
methanol-d4): δ 174.97, 172.71, 171.95, 171.05, 167.46, 137.41, 137.39, 134.76, 
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128.05, 128.00, 127.98,127.97,127.54, 127.52, 125.22, , 96.18, 79.67, 72.80, 69.98, 
68.88, 62.39, 61.25, 59.06, 57.96, 56.42, 53.31, 39.82, 31.67, 29.30, 29.13,29.05 26.75, 






In a similar way as described for the preparation of 7, a solution of 39 (20 mg, 0.0218 
mmol) in a mixture of dichloromethane (3 ml), TFA (2.75 ml) and H2O (0.25 ml) was 
stirred at 0 °C for 1 h. The solvents were then removed in vacuo. The residue was 
subjected to flash column chromatography (CH2Cl2/MeOH/H2O, 5:1) to afford 9 (10 mg, 
72%) as white solid. Rf 0.47 (CH2Cl2/MeOH/H2O, 5:1); [α]D22 + 30.2 (C 1.0, 
CHCl3/MeOH, 1:1). 1H NMR (500 MHz, methanol-d4): δ 7.95 (d, J = 2.1 Hz, 1H), 7.83 (d, 
J = 8.5 Hz, 1H), 7.71 (dd, J = 8.5, 2.1 Hz, 1H), 7.42 – 7.23 (m, 5H), 4.84 (d, J = 3.6 Hz, 
1H), 4.71 (d, J = 12.0 Hz, 1H), 4.51 (d, J = 12.0 Hz, 1H), 4.36 (m, 3H), 4.02 (dd, J = 
10.6, 3.6 Hz, 1H), 3.91 – 3.81 (m, 1H), 3.58 – 3.48 (m, 1H), 3.37 (m, 4H), 2.23 (s, 3H), 
1.87 (s, 3H), 1.61 (m, 3H), 1.53 (d, J = 7.1 Hz, 3H), 1.43 (d, J = 6.7 Hz, 3H), 1.31 (br s, 
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26H), 0.92 (t, J = 6.7 Hz, 3H).13C NMR (126 MHz, methanol-d4): δ 174.99, 172.76, 
171.97, , 167.43, 159.93, 137.43, 134.77, 131.33, 128.73, 127.99 , 127.97, 127.49, 
125.10, 125.08, 123.33, 95.99, 85.93, 79.67, 77.16, 72.82, 69.91, 68.68, 64.78, 62.38, 
61.15, 58.92, 58.16, 56.43, 55.40, 53.29, 49.90, 46.16, 45.11, 39.71, 31.70, 29.42, 
29.39 ,29.35, 29.32,29.09, 26.72, 22.36, 21.36, 18.09, 16.16, 13.08. MS m/z calcd for 
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13C NMR spectrum for compound 20. (126 MHz, chloroform-d)  
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1H NMR spectrum of compound 21. (500 MHz, chloroform-d)  
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13C NMR spectrum for compound 21. (126 MHz, chloroform-d)  
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1H NMR spectrum of compound 28. (500 MHz, chloroform-d)) 
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1H NMR spectrum for compound 39 (500 MHz, DMSO-d6)  
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1H NMR spectrum for compound 42 (500 MHz, methanol-d4)  
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1H NMR spectrum for compound 7 (500 MHz, methanol-d4)  
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MALDI-MS m/z calcd for C46H71N5O10: 854.099; found: 876.52 [M+Na]. 
 
